- Did you mean
- mrsa
Search results - 28 results
mRNA Substances for the production of mRNA vaccines for human use (5.39)
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Wim Van Molle Source: EDQM, Volume European Pharmacopoeia (Ph. Eur.) 12.1 (2025) Service: Qualité des vaccins et produits sanguins Kwaliteit van vaccins en bloedpro ...
mRNA vaccines for human use (5.36)
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Wim Van Molle Source: EDQM, Volume European Pharmacopoeia (Ph. Eur.) 12.1 (2025) Service: Qualité des vaccins et produits sanguins Kwaliteit van vaccins en bloedpro ...
DNA templates for the preparation of mRNA substances (5.40)
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Wim Van Molle Source: EDQM, Volume European Pharmacopoeia (Ph. Eur.) 12.1 (2025) Service: Qualité des vaccins et produits sanguins Kwaliteit van vaccins en bloedpro ...
COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients
COVID-19 mRNA vaccination in SARS-CoV-2 naive hemodialysis recipients (HDR) have already been identified. Clinical factors influencing hybrid immunity induced by SARS-CoV-2 infection and vaccination in HDR ...
Best practices for lot release of mRNA vaccines
Workshop, WHO, Cairo, Egypt (2024) Keywords: batch release mRNA Quality vaccine Health Topics: Vaccine batch conformity Vaccin lot conformiteit Conformité de lot de vaccin Service: Qualité des vaccins et ...
Guideline for Respiratory Syncytial Virus (mRNA) Vaccine
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: Tesolin, L.; Bruysters, M.; Campitelli, L.; Pullirsch, D.; Oppling, V.; Garcia, D. Source: EDQM, Strasbourg (F), p.18 (2024) Accession Number: PA/PH/OMCL (24) 66 DEF ...
Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients
associated with reduced immune responses to primary COVID-19 mRNA vaccination in kidney transplant recipients (KTR s). In healthy individuals, prior SARS- COV-2 infection is associated with increased vaccine ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 ...
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
Transplantation Prospective Studies SARS-CoV-2 Transplant Recipients Vaccination Abstract: As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA ...